While data confirmation is needed, recent findings may prove beneficial in identifying patients at a high risk of developing prostate cancer.
Researchers used a sophisticated combination of proteomics and metabolomics to show how RCC reprograms its metabolism and evades the immune system.
Common gastrointestinal symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.
[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- CD151—A Striking Marker for Cancer Therapy
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- Multigene Cancer-Susceptibility Tests Require New Approaches to Patient Counseling
- Addition of Levetiracetam May Improve Survival for Glioblastoma
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Identifying Genetic Variations Associated with Risk of Prostate Cancer
- Adding Radiotherapy to ADT Only Slightly Impacts Quality of Life in Prostate Cancer
- Adding Bevacizumab Has No Impact on Quality of Life in Glioblastoma
- First Oncolytic Immunotherapy Improves Durable Response Rate in Melanoma
- Adding Bevacizumab Effective in Chinese Patients with Nonsquamous Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|